The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC)

doi:10.1016/j.lungcan.2026.109582

The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC)

2026-08-14

0

PRE

AI

DOI：10.1016/j.lungcan.2026.109582

Original

Original request for help

Save

Abstract

En 中文

• L858R and TP53 independently predict worse rwPFS and OS on front-line osimertinib. • All TP53 variants, regardless of mutation type, predict inferior survival. • L858R combined with a TP53 co-mutation was associated with the shortest survival. • L858R/TP53-mutant NSCLC had a 21.3 month median OS and 5.4% 5-year OS. • EGFR subtype plus TP53 status can identify patients for intensive therapies or trials.

The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC)

Abstract

Journal

Organization